Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511489-35-00

Acronym

CVAY736J12101

Enrollment

Registered

2024-07-02

Start date

2022-01-24

Completion date

2024-10-02

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory Non Hodgkin Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026